Literature DB >> 23659348

Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5.

Katharine A Phillips1, Ashley S Hart1, Helen Blair Simpson2, Dan J Stein3.   

Abstract

The core feature of body dysmorphic disorder (BDD) is distressing or impairing preoccupation with nonexistent or slight defects in one's physical appearance. BDD beliefs are characterized by varying degrees of insight, ranging from good (ie, recognition that one's BDD beliefs are not true) through "absent insight/delusional" beliefs (ie, complete conviction that one's BDD beliefs are true). The Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev. (DSM-III-R) and The Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) classified BDD's nondelusional form in the somatoform section of the manual and its delusional form in the psychosis section, as a type of delusional disorder, somatic type (although DSM-IV allowed double-coding of delusional BDD as both a psychotic disorder and BDD). However, little or no evidence on this issue was available when these editions were published. In this article, we review the classification of BDD's delusional and nondelusional variants in earlier editions of DSM and the limitations of their approaches. We then review empirical evidence on this topic, which has become available since DSM-IV was developed. Available evidence indicates that across a range of validators, BDD's delusional and nondelusional variants have many more similarities than differences, including response to pharmacotherapy. Based on these data, we propose that BDD's delusional and nondelusional forms be classified as the same disorder and that BDD's diagnostic criteria include an insight specifier that spans a range of insight, including absent insight/delusional BDD beliefs. We hope that this recommendation will improve care for patients with this common and often-severe disorder. This increased understanding of BDD may also have implications for other disorders that have an "absent insight/delusional" form.

Entities:  

Mesh:

Year:  2013        PMID: 23659348      PMCID: PMC4948290          DOI: 10.1017/S1092852913000266

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  40 in total

Review 1.  Hoarding disorder: a new diagnosis for DSM-V?

Authors:  David Mataix-Cols; Randy O Frost; Alberto Pertusa; Lee Anna Clark; Sanjaya Saxena; James F Leckman; Dan J Stein; Hisato Matsunaga; Sabine Wilhelm
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

2.  A 12-month follow-up study of the course of body dysmorphic disorder.

Authors:  Katharine A Phillips; Maria E Pagano; William Menard; Robert L Stout
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

3.  Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.

Authors:  K A Phillips; S L McElroy; M M Dwight; J L Eisen; S A Rasmussen
Journal:  J Clin Psychiatry       Date:  2001-02       Impact factor: 4.384

Review 4.  Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V.

Authors:  James F Leckman; Damiaan Denys; H Blair Simpson; David Mataix-Cols; Eric Hollander; Sanjaya Saxena; Euripedes C Miguel; Scott L Rauch; Wayne K Goodman; Katharine A Phillips; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

5.  Severity of interpersonal problems in individuals with body dysmorphic disorder.

Authors:  Elizabeth R Didie; Elizabeth H Loerke; Sarah E Howes; Katharine A Phillips
Journal:  J Pers Disord       Date:  2012-06

6.  Insight in eating disorders: clinical and cognitive correlates.

Authors:  G Konstantakopoulos; K Tchanturia; S A Surguladze; A S David
Journal:  Psychol Med       Date:  2011-01-07       Impact factor: 7.723

7.  A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.

Authors:  Katharine A Phillips; Ralph S Albertini; Steven A Rasmussen
Journal:  Arch Gen Psychiatry       Date:  2002-04

8.  Delusional versus nondelusional body dysmorphic disorder.

Authors:  Serafino G Mancuso; Natalie P Knoesen; David J Castle
Journal:  Compr Psychiatry       Date:  2009-07-09       Impact factor: 3.735

9.  Initial reliability and validity of a new retrospective measure of child abuse and neglect.

Authors:  D P Bernstein; L Fink; L Handelsman; J Foote; M Lovejoy; K Wenzel; E Sapareto; J Ruggiero
Journal:  Am J Psychiatry       Date:  1994-08       Impact factor: 18.112

10.  The Modified Hamilton Rating Scale for Depression: reliability and validity.

Authors:  I W Miller; S Bishop; W H Norman; H Maddever
Journal:  Psychiatry Res       Date:  1985-02       Impact factor: 3.222

View more
  5 in total

1.  Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.

Authors:  Katharine A Phillips; Aparna Keshaviah; Darin D Dougherty; Robert L Stout; William Menard; Sabine Wilhelm
Journal:  Am J Psychiatry       Date:  2016-04-08       Impact factor: 18.112

2.  Cytoarchitectonically Defined Volumes of Early Extrastriate Visual Cortex in Unmedicated Adults With Body Dysmorphic Disorder.

Authors:  Jamie D Feusner; Florian Kurth; Eileen Luders; Ronald Ly; Wan-Wa Wong
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2021-10-21

3.  Body dysmorphic disorder: A diagnostic challenge in adolescence.

Authors:  Yanga Thungana; Karis Moxley; Anusha Lachman
Journal:  S Afr J Psychiatr       Date:  2018-06-28       Impact factor: 1.550

Review 4.  Pharmacological Treatment of Body Dysmorphic Disorder.

Authors:  Kevin Hong; Vera Nezgovorova; Genoveva Uzunova; Danya Schlussel; Eric Hollander
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

Review 5.  DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions.

Authors:  Charles B Nemeroff; Daniel Weinberger; Michael Rutter; Harriet L MacMillan; Richard A Bryant; Simon Wessely; Dan J Stein; Carmine M Pariante; Florian Seemüller; Michael Berk; Gin S Malhi; Martin Preisig; Martin Brüne; Paul Lysaker
Journal:  BMC Med       Date:  2013-09-12       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.